Skip to search formSkip to main contentSkip to account menu

tipifarnib

Known as: (+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, 2 (1H))-quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-,(+)- 
A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an… 
National Institutes of Health

Related topics

Related topics

11 relations
Angiogenesis InhibitionInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Broader (2)

Antineoplastic AgentsQuinolones

Narrower (2)

R115777Zarnestra

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on… 
Review
2010
Review
2010
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib
Importance of the field: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) incidence in the United States increases… 
2009
2009
Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples
Purpose: To show whether the inhibitory effects of the cholesterol synthesis inhibitor simvastatin on human CD34+ acute myeloid… 
2008
2008
Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features
Purpose: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features. Such… 
Review
2007
Review
2007
Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.
Review
2007
Review
2007
Clinical activity of tipifarnib in hematologic malignancies
Farnesyltransferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase. Initially… 
Highly Cited
2004
Highly Cited
2004
Tipifarnib (ZARNESTRATM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.
Farnesyltransferase inhibitors (FTI) make up a novel class of anti-cancer agents that competitively and selectively inhibit… 
2004
2004
Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.
Review
2004
Review
2004
Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
Farnesyltransferase (FT) inhibitors were originally designed as anticancer agents, and were thought to act by inhibiting the… 
Highly Cited
2002
Highly Cited
2002
Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3…
Accelerator mass spectrometry (AMS) has been used in a human mass balance and metabolism study to analyze samples taken from four… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)